Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for ...

Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite ...

Covalent BTK inhibitors and Bcl-2 inhibitors are primary treatments for CLL, but alternatives are needed for relapsed or refractory cases. Treatment sequencing is vital, with potential switches ...

First-line therapy for chronic lymphocytic leukaemia (CLL) is rapidly evolving, with a recent phase III trial showing that fixed-duration therapy with BCL-2 inhibitor-based doublet regimens is ...

For (adult) patients with relapsed or refractory chronic lymphocytic leukemia (CLL), a new line of treatment has been ...

SAN DIEGO — Treatment with the oral Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib in combination with venetoclax was associated with improved progression-free survival compared with ...

The "Test Before Treat" campaign is specifically aimed at the approximately 50% of CLL and SLL patients who have high-risk molecular features that can impact the efficacy of some treatments, per ...

ISTANBUL, TR / ACCESS Newswire / June 17, 2026 / Lymphocytic leukemia is a type of blood cancer that affects lymphocytes, a ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

A cancer diagnosis hits like a thunderbolt, changing lives instantly and profoundly. Victor Gonzalez, senior director of patient programs and support services at The Lymphoma Research Foundation, ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center ...